期刊文献+

干扰素不良反应及其处理 被引量:19

The adverse reactions of interferon and its management
暂未订购
导出
摘要 干扰素是机体细胞对病毒感染或各种生物诱生作用反应而产生并分泌的一类具有多种生物活性的糖蛋白,具有抗病毒、抗肿瘤和免疫调节作用,其重组药物广泛应用于临床,但药物的不良反应也是较突出的问题。充分了解干扰素的不良反应是临床干扰素推广应用的重要前提。本文简要综述干扰素临床应用中出现的不良反应、产生机制、影响因素及其治疗措施。 Interferon (IFN) is a kind ofbioactive glycoprotein, which is synthesized and secreted by virus-infected or other biological-induced cells. IFN plays a significant role in inhibiting virus as well as oncoma and immunomodulation, and has an extensive clinical application. However, the adverse reactions of IFN is also a problem exerted. Accordingly, a better comprehension for IFN is prerequisite for its application. In this review, the adverse reactions of IFN and its mechanisms, influential factors, as well as management were summarized.
出处 《世界临床药物》 CAS 2009年第6期334-338,共5页 World Clinical Drug
关键词 干扰素 不良反应 肝炎 病毒性 处理 interferon adverse reaction hepatitis viral management
  • 相关文献

参考文献4

二级参考文献37

  • 1Fried MW, Schiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for patients with chronic hepatitis C virus infection. N Engl J Med, 2002, 347: 975-982.
  • 2Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet,2001, 358: 958-965.
  • 3Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology, 2003, 124: 1711-1719.
  • 4DE Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis c virus infection:role of membrane oxidative damage. Hepatology,2000, 31: 997-1004.
  • 5Shiffman ML,Hofmann CM, Luketic VA, et al. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alfa-2b for treatment of chronic hepatitis C. J Hepatology,1998, 28:382-389.
  • 6Pockros PJ, Duchini A, McMillar R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection.Am J Gastroenterol, 2002, 97: 2040-2045.
  • 7Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology, 1997, 26: 206-210.
  • 8Perry CM,Jarvis B. Peginterferon α 2a (40 kD): A review of its use in the management of chronic hepatitis C. Drugs ,2001,61:2263
  • 9Lam NP, Neunann AU, Gretch DR, et al. Dose dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology, 1997,26: 226
  • 10Kozlowski A, Charles SA, Harris MJ. Development of pegylated interferons for the treament of chronic hepatitis C. Biodrugs, 2001,15:419

共引文献59

同被引文献205

引证文献19

二级引证文献87

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部